๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Manchester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Manchester, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 670 Birmingham 470 Glasgow 437 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca73 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC28 Hoffmann-La Roche25 Eli Lilly and Company17
Site city
London2010 Manchester670 Birmingham470 Glasgow437 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Manchester

670 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
Gilead Sciences
Phase 3
1,021
London, Manchester
2022-10-12
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740Advanced Solid Tumors
Bayer
Phase 1
129
Manchester, Sutton
2022-10-11
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 1
196
London, Manchester, Oxfordshire
2022-10-04
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth
2022-10-04
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
Ellipses Pharma
Phase 1/2
265
London, Manchester, Sheffield
2022-09-30
Active, closed
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRฮฑ) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
NCT05461170Hepatitis D, Chronic
Vir Biotechnology, Inc.
Phase 2
95
Birmingham, London, Manchester
2022-09-17
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
London, Manchester, Birmingham, Leeds
2022-09-13
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
AstraZeneca
Phase 2
454
Cambridge, Dundee, London, Manchester
2022-09-06
Active, closed
Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Devices for Medial Patellofemoral Ligament (MPFL) Reconstruction
NCT05264389Medial Patellofemoral Dislocation
Xiros Ltd
Observational
59
Great Yarmouth, Manchester, Stoke-on-Trent, Winchester, Yeovil
2022-09-05
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
Stemline Therapeutics, Inc.
Phase 1/2
73
Leicester, Liverpool, London, Manchester
2022-08-31
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono Research & Development Institute, Inc.
Phase 2
256
London, Manchester, Preston
2022-08-17
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
London, Manchester
2022-08-12
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
AstraZeneca
Phase 2
194
Cambridge, Chelsea, Manchester, Northwood
2022-08-11
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropinยฎ Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
Novo Nordisk A/S
Phase 3
412
Cambridge, Hull, Liverpool, London, Manchester, Tooting
2022-08-10
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
Phase 3
373
Dorchester, London, Manchester, Nottingham
2022-08-03
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
London, Manchester, Wolverhampton
2022-08-03
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Recruiting
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
NCT05163288Niemann-Pick Disease, Type C
IntraBio Inc
Phase 3
53
London, Manchester
2022-06-30
Active, closed
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Corcept Therapeutics
Phase 3
381
Brighton, Taunton, Cheltenham, London, Manchester, Northwood
2022-06-29
Active, closed
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
NCT05181618Severe Hemophilia A, Moderate Hemophilia A
Hoffmann-La Roche
Phase 4
136
London, Manchester
2022-06-20
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632Adult Acute Myeloid Leukemia
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1/2
840
Sutton, Edinburgh, London, Manchester
2022-06-09
Active, closed
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
NCT05428969Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Faron Pharmaceuticals Ltd
Phase 1/2
181
Manchester, Truro
2022-06-02
Active, closed
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
174
Cambridge, Glasgow, Manchester, Plymouth
2022-06-02
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
London, Manchester, Newcastle upon Tyne
2022-05-23
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
Enliven Therapeutics
Phase 1
250
Glasgow, London, Manchester
2022-05-22
Active, closed
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254Metastatic Melanoma, Unresectable Melanoma
IO Biotech
Phase 3
407
London, Manchester, Oxford
2022-05-17
Active, closed
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged โ‰ฅ2 Years With Congenital Hyperinsulinism (CHI)
NCT04732416Congenital Hyperinsulinism
Hanmi Pharmaceutical Company Limited
Phase 2
17
London, Manchester
2022-05-05
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Glasgow, Cambridge, London, Manchester, Merseyside
2022-05-03
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Cogent Biosciences, Inc.
Phase 3
482
Cambridge, Glasgow, London, Manchester, Sheffield
2022-04-14
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
Bayer
Phase 3
219
London, Manchester, Nottingham, Glasgow
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Manchester, Northwood, Birmingham
2022-03-24
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
GlaxoSmithKline
Phase 1
152
Manchester, Sutton
2022-03-22
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Recruiting
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700Solid Tumors
ORIC Pharmaceuticals
Phase 1/2
350
Manchester
2022-03-10
Recruiting
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
NCT05295433Methylmalonic Acidemia
ModernaTX, Inc.
Phase 1/2
56
Birmingham, Manchester
2022-03-08
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Zogenix, Inc.
Phase 3
87
Bristol, London, Manchester, Sheffield
2022-03-08
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche
Phase 1
332
Manchester, Oxford
2022-03-07
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
London, Sutton, Manchester
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Manchester, Sheffield
2022-02-21
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2/3
286
London, Cambridge, Manchester
2022-02-11
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320Crohn's Disease (CD)
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Manchester, Glasgow, London
2022-02-03
Active, closed
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287Autosomal Dominant Hypocalcemia
Calcilytix Therapeutics, Inc., a BridgeBio company
Observational
95
Manchester
2022-01-20
Recruiting
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1/2
359
London, Manchester
2022-01-04
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Agios Pharmaceuticals, Inc.
Phase 3
194
Cambridge, Manchester, London
2021-12-20
By invitation
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
NCT05145010Achondroplasia
QED Therapeutics, a BridgeBio company
Phase 2
300
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
Amgen
Phase 2
222
London, Manchester
2021-12-01
Active, closed
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)
AstraZeneca
Phase 3
145
London, Manchester
2021-11-19
Active, closed
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
NCT05130450Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals, Inc.
Phase 3
60
Manchester
2021-11-18
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Recruiting
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
NCT05130437Propionic Acidemia
ModernaTX, Inc.
Phase 1/2
50
Manchester, Birmingham, London
2021-11-09
Recruiting
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
NCT05104515Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Oxford Vacmedix UK Ltd.
Phase 1
36
London, Manchester, Oxford
2021-11-01
Recruiting
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894Generalized Myasthenia Gravis
argenx
Phase 2/3
12
London, Manchester, Oxford
2021-10-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 3
303
Cambridge, Leeds, London, Manchester
2021-10-26
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Active, closed
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372Mesothelioma
Novartis Pharmaceuticals
Phase 1
137
Manchester
2021-10-21
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Cambridge, Bradford, Manchester
2021-10-11
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
Inhibrx Biosciences, Inc
Phase 2
206
London, Manchester, Oxford
2021-09-23
Active, closed
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
NCT04776252HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
2,000
East Sussex, Bristol, London, Manchester
2021-09-15
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2
42
London, Manchester, Newcastle upon Tyne
2021-09-14
Active, closed
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
NCT04973163Solid Tumors, KRAS Mutation
Boehringer Ingelheim
Phase 1
30
Manchester
2021-09-09
Active, closed
Clinical Study for Treatment-naรฏve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776Glycogen Storage Disease Type II
Sanofi
Phase 3
17
London, Manchester
2021-09-01
Active, closed
A Study of AL102 in Patients With Progressing Desmoid Tumors
NCT04871282Desmoid, Desmoid Tumor
Immunome, Inc.
Phase 2/3
198
Edinburgh, Cambridge, London, Manchester
2021-09-01
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow
2021-08-19
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
Travere Therapeutics, Inc.
Phase 2
67
Bristol, Glasgow, Liverpool, London, Manchester
2021-08-12
Active, closed
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT05005975EPP, XLP
Tanabe Pharma America, Inc.
Phase 3
286
Manchester, London
2021-08-10
Recruiting
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288Renal Allograft Recipients
Bristol-Myers Squibb
Phase 3
102
Manchester, Nottingham
2021-07-21
Active, closed
Effectiveness of the EMPOWERโ„ข Modular Pacing System and EMBLEMโ„ข Subcutaneous ICD to Communicate Antitachycardia Pacing
NCT04798768Tachycardia, Ventricular, Arrhythmia, Ventricular
Boston Scientific Corporation
Not applicable
297
Leeds, Liverpool, Manchester, Southampton
2021-07-20
Recruiting
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFฮฑ Inhibitor Treatment
NCT04908189Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
729
London, Bradford, Hull, Liverpool, Manchester
2021-07-15
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
315
Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading
2021-06-30
Active, closed
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
NCT04411654Gaucher Disease, Type 2
Prevail Therapeutics
Phase 1/2
7
Manchester
2021-06-29
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients โ‰ค6 Months of Age With Infantile-onset Pompe Disease (IOPD)
NCT04848779Glycogen Storage Disease Type II
Sanofi
Observational
16
London, Manchester
2021-06-10
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo
Phase 3
490
Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester
2021-05-21
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 2
170
Chelsea, London, Manchester, Birmingham
2021-05-07
Rows per page Showing 401–500 of 670
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester?page=5

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 24 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 670 of those studies with a site in Manchester.

How many clinical trials are recruiting in Manchester?

336 of the 670 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:15 UTC sync. A further 8 have not yet opened recruitment, 314 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.